Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-Polycythemia Vera MF (Post-PV-MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Not applicableUnknownNCT05883904
What this trial is testing

Real World Evidence of Fedratinib Effectiveness in MF

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Gruppo Italiano Malattie EMatologiche dell'Adulto 93
Not applicableAvailableNCT04745637
What this trial is testing

Managed Access Programs for INC424, Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)+4 more
Novartis Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT07340138
What this trial is testing

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Novartis Pharmaceuticals 3
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics Incorporated 100
Not applicableStudy completedNCT05044026
What this trial is testing

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 1,012
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Early research (Phase 1)Ended earlyNCT03935555
What this trial is testing

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Samus Therapeutics, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT04629508
What this trial is testing

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocythemia
Incyte Corporation 4
Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)Study completedNCT01969838
What this trial is testing

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 432
Large-scale testing (Phase 3)Active Not RecruitingNCT04603495
What this trial is testing

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Novartis Pharmaceuticals 430
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT01423851
What this trial is testing

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
NS Pharma, Inc. 77
Early research (Phase 1)Ended earlyNCT01291784
What this trial is testing

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more
John Mascarenhas 3
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Who this might be right for
Myeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more
Celgene 313
Testing effectiveness (Phase 2)Study completedNCT01340651
What this trial is testing

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Who this might be right for
Myelofibrosis
Incyte Corporation 41
Next Page